{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T04:03:24Z","timestamp":1778126604836,"version":"3.51.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Res."],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Peripheral T-cell lymphomas (PTCLs) are a rare and heterogeneous group of aggressive malignancies. This study aimed to comprehensively analyze patients diagnosed with PTCLs in Korea, evaluating treatment outcomes, including transplantation and long-term survival.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patients and methods<\/jats:title>\n            <jats:p>In this retrospective study, clinical data from the National Health Insurance Service on patients with PTCL were investigated. Most patients diagnosed with mature T-cell lymphomas and natural killer (NK)\/T-cell lymphomas between January 2005 and December 2022 in Korea were included. Incidence rates of each subtype and survival outcomes of both treated and untreated patients were analyzed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 12,573 patients were analyzed. PTCL not otherwise specified (PTCL-NOS) and extranodal NK\/T-cell lymphoma were the most frequently diagnosed, followed by angioimmunoblastic T-cell lymphoma (AITL). Compared to the general population, the relative survival rate was highest in anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma. With a median follow-up of 6.7\u00a0years, the 3-year and 5-year progression-free survival (PFS) rates among treated patients were 44.0% and 39.5%, while the overall survival (OS) rates were 48.6% and 43.5%, respectively. Kaplan\u2013Meier survival curves indicated that patients who added etoposide to the CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) regimen showed improved PFS and OS. In addition, autologous stem cell transplantation significantly improved PFS and OS, particularly in the PTCL-NOS and AITL subtypes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Patients who received etoposide-containing CHOP-based regimens had improved treatment outcomes. The survival benefits of consolidative autologous stem cell transplantation (auto-SCT) were evident in PTCL-NOS and AITL.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s44313-025-00095-1","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T13:22:12Z","timestamp":1755782532000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-world data on long-term outcomes in patients with T-cell lymphomas: a nationwide study of Korea"],"prefix":"10.1007","volume":"60","author":[{"given":"Dong Won","family":"Baek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung Min","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youngeun","family":"Jang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunji","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hee Jeong","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joon Ho","family":"Moon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hasung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hoseob","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang Kyun","family":"Sohn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,21]]},"reference":[{"issue":"9","key":"95_CR1","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1038\/bjc.2015.94","volume":"112","author":"A Smith","year":"2015","unstructured":"Smith A, Crouch S, Lax S, Li J, Painter D, Howell D, et al. Lymphoma incidence, survival and prevalence 2004\u20132014: sub-type analyses from the UK\u2019s haematological malignancy research network. Br J Cancer. 2015;112(9):1575\u201384.","journal-title":"Br J Cancer"},{"issue":"8","key":"95_CR2","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1002\/ajh.26270","volume":"96","author":"JM Zain","year":"2021","unstructured":"Zain JM, Hanona P. Aggressive T-cell lymphomas: 2021 updates on diagnosis, risk stratification and management. Am J Hematol. 2021;96(8):1027\u201346.","journal-title":"Am J Hematol"},{"issue":"20","key":"95_CR3","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375\u201390.","journal-title":"Blood"},{"issue":"7","key":"95_CR4","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36(7):1720\u201348.","journal-title":"Leukemia"},{"key":"95_CR5","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1182\/blood-2014-04-573089","volume":"124","author":"F Ellin","year":"2014","unstructured":"Ellin F, Landstr\u00f6m J, Jerkeman M, Relander T. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. Blood. 2014;124:1570\u20137.","journal-title":"Blood"},{"issue":"5","key":"95_CR6","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1111\/bjh.14477","volume":"176","author":"D Chihara","year":"2017","unstructured":"Chihara D, Fanale MA, Miranda RN, Noorani M, Westin JR, Nastoupil LJ, et al. The survival outcome of patients with relapsed\/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma. Br J Haematol. 2017;176(5):750\u20138.","journal-title":"Br J Haematol"},{"issue":"7","key":"95_CR7","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1002\/cncr.30416","volume":"123","author":"KR Carson","year":"2017","unstructured":"Carson KR, Horwitz SM, Pinter-Brown LC, Rosen ST, Pro B, His ED, et al. A prospective cohort study of patients with peripheral T-cell lymphoma in the United States. Cancer. 2017;123(7):1174\u201383.","journal-title":"Cancer"},{"issue":"11","key":"95_CR8","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1093\/annonc\/mdu443","volume":"25","author":"JS Abramson","year":"2014","unstructured":"Abramson JS, Feldman T, Kroll-Desrosiers AR, Muffly LS, Winer E, Flowers CR, et al. Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy. Ann Oncol. 2014;25(11):2211\u20137.","journal-title":"Ann Oncol"},{"key":"95_CR9","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","volume":"393","author":"S Horwitz","year":"2019","unstructured":"Horwitz S, O\u2019Connor OA, Pro B, Illidge T, Fanale M, Advani R, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019;393:229\u201340.","journal-title":"Lancet"},{"issue":"26","key":"95_CR10","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1182\/blood.2019001821","volume":"134","author":"SK Barta","year":"2019","unstructured":"Barta SK, Gong JZ, Porcu P. Brentuximab vedotin in the treatment of CD30+ PTCL. Blood. 2019;134(26):2339\u201345.","journal-title":"Blood"},{"key":"95_CR11","doi-asserted-by":"crossref","unstructured":"Horwitz SM, Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, et al. NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016. J Natl Compr Canc Netw. 2016;14(9):1067\u20131079.","DOI":"10.6004\/jnccn.2016.0117"},{"issue":"Suppl 5","key":"95_CR12","doi-asserted-by":"publisher","first-page":"v108","DOI":"10.1093\/annonc\/mdv201","volume":"26","author":"F d\u2019Amore","year":"2015","unstructured":"d\u2019Amore F, Gaulard P, Tr\u00fcmper L, Corradini P, Kim WS, Specht L, et al. Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v108\u201315.","journal-title":"Ann Oncol"},{"issue":"19","key":"95_CR13","first-page":"2646","volume":"137","author":"N Schmitz","year":"2021","unstructured":"Schmitz N, Truemper L, Bouabdallah K, Ziepert M, Leclerc M, Cartron G, et al. A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL. Blood. 2021;137(19):2646\u201356.","journal-title":"Blood"},{"issue":"1","key":"95_CR14","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41408-023-00868-w","volume":"13","author":"DW Baek","year":"2023","unstructured":"Baek DW, Moon JH, Lee JH, Kang K, Lee HS, Eom H, et al. Real-world data of long-term survival in patients with T-cell lymphoma who underwent stem cell transplantation. Blood Cancer J. 2023;13(1):95.","journal-title":"Blood Cancer J"},{"issue":"1","key":"95_CR15","doi-asserted-by":"publisher","first-page":"222","DOI":"10.4143\/crt.2017.093","volume":"50","author":"H Lee","year":"2018","unstructured":"Lee H, Park HJ, Park E, Ju HY, Oh CM, Kong H, et al. Nationwide statistical analysis of lymphoid malignancies in Korea. Cancer Res Treat. 2018;50(1):222\u201338.","journal-title":"Cancer Res Treat"},{"key":"95_CR16","first-page":"101","volume":"6","author":"F Ederer","year":"1961","unstructured":"Ederer F, Axtell LM, Cutler SJ. The relative survival rate: a statistical methodology. Natl Cancer Inst Monogr. 1961;6:101\u201321.","journal-title":"Natl Cancer Inst Monogr"},{"key":"95_CR17","doi-asserted-by":"crossref","unstructured":"Dickman PW, Sloggett A, Hills M, Hakulinen T. Regression models for relative survival. Stat Med. 2004;15;23(1):51\u201364.","DOI":"10.1002\/sim.1597"},{"issue":"25","key":"95_CR18","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","volume":"26","author":"J Vose","year":"2008","unstructured":"Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124\u201330.","journal-title":"J Clin Oncol"},{"key":"95_CR19","volume":"10","author":"SE Yoon","year":"2021","unstructured":"Yoon SE, Song Y, Kin SJ, Yoon DH, Chen T, Koh Y, et al. Comprehensive analysis of peripheral T-cell and natural killer\/T-cell lymphoma in Asian patients: A multinational, multicenter, prospective registry study in Asia. Lancet Reg Health West Pac. 2021;10: 100126.","journal-title":"Lancet Reg Health West Pac"},{"issue":"14","key":"95_CR20","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJM199304083281404","volume":"328","author":"RI Fisher","year":"1993","unstructured":"Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin\u2019s lymphoma. N Engl J Med. 1993;328(14):1002\u20136.","journal-title":"N Engl J Med"},{"key":"95_CR21","doi-asserted-by":"publisher","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","volume":"116","author":"N Schmitz","year":"2010","unstructured":"Schmitz N, Tr\u00fcmper L, Ziepert M, Nickelsen M, Ho AD, Metzner B, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood. 2010;116:3418\u201325.","journal-title":"Blood"},{"key":"95_CR22","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1007\/s00277-019-03694-y","volume":"98","author":"A Janikova","year":"2019","unstructured":"Janikova A, Chloupkova R, Campr V, Klener P, Hamouzova J, Belada D, et al. First-line therapy for T cell lymphomas: a retrospective population-based analysis of 906 T cell lymphoma patients. Ann Hematol. 2019;98:1961\u201372.","journal-title":"Ann Hematol"},{"key":"95_CR23","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1111\/bjh.14740","volume":"178","author":"H Cederleuf","year":"2017","unstructured":"Cederleuf H, Pedersen MB, Jerkeman M, Relander T, d\u2019Amore F, Ellin F. The addition of etoposide to CHOP is associated with improved outcome in ALK+ adult anaplastic large cell lymphoma: a Nordic Lymphoma Group study. Br J Haematol. 2017;178:739\u201346.","journal-title":"Br J Haematol"},{"key":"95_CR24","doi-asserted-by":"publisher","first-page":"e562","DOI":"10.3324\/haematol.2018.213512","volume":"104","author":"D Sibon","year":"2019","unstructured":"Sibon D, Nguyen D, Schmitz N, Suzuki R, Feldman A, Gressin R, et al. ALK-positive anaplastic large-cell lymphoma in adults: an individual patient data pooled analysis of 263 patients. Haematologica. 2019;104:e562\u20135.","journal-title":"Haematologica"},{"issue":"1","key":"95_CR25","doi-asserted-by":"publisher","first-page":"e27","DOI":"10.3324\/haematol.2015.131151","volume":"101","author":"K Dunleavy","year":"2016","unstructured":"Dunleavy K, Pittaluga S, Shovlin M, Roschewski M, Lai C, Steinberg SM, et al. Phase II trial of dose-adjusted EPOCH in untreated systemic anaplastic large cell lymphoma. Haematologica. 2016;101(1):e27\u20139.","journal-title":"Haematologica"},{"issue":"12","key":"95_CR26","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.3324\/haematol.2017.167742","volume":"102","author":"Y Maeda","year":"2017","unstructured":"Maeda Y, Nishimori H, Yoshida I, Hiramatsu Y, Uno M, Masaki Y, et al. Dose-adjusted EPOCH chemotherapy for untreated peripheral T-cell lymphomas: a multicenter phase II trial of West-JHOG PTCL0707. Haematologica. 2017;102(12):2097\u2013103.","journal-title":"Haematologica"},{"issue":"12","key":"95_CR27","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1093\/annonc\/mdp211","volume":"20","author":"M Nickelsen","year":"2009","unstructured":"Nickelsen M, Ziepert M, Zeynalova S, Glass B, Metzner B, Leithaeuser M, et al. High-dose CHOP plus etoposide (MegaCHOEP) in T-cell lymphoma: a comparative analysis of patients treated within trials of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Ann Oncol. 2009;20(12):1977\u201384.","journal-title":"Ann Oncol"},{"issue":"9","key":"95_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14092332","volume":"14","author":"D Sibon","year":"2022","unstructured":"Sibon D. Peripheral T-cell lymphomas: therapeutic approaches. Cancers. 2022;14(9): 2332.","journal-title":"Cancers"},{"issue":"25","key":"95_CR29","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","volume":"30","author":"F d\u2019Amore","year":"2012","unstructured":"d\u2019Amore F, Relander T, Lauritzsen GF, Jantunen E, Hagberg H, Anderson H, et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol. 2012;30(25):3093\u20139.","journal-title":"J Clin Oncol"},{"key":"95_CR30","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1200\/JCO.2008.17.4870","volume":"27","author":"P Reimer","year":"2009","unstructured":"Reimer P, R\u00fcdiger T, Geissinger E, Weissinger F, Nerl C, Schmitz N, et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol. 2009;27:106\u201313.","journal-title":"J Clin Oncol"},{"key":"95_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.63","volume":"6","author":"M Wilhelm","year":"2016","unstructured":"Wilhelm M, Smetak M, Reimer P, Geissinger E, Ruediger T, Metzner B, et al. First-line therapy of peripheral T-cell lymphoma: extension and long-term follow-up of a study investigating the role of autologous stem cell transplantation. Blood Cancer J. 2016;6: e452.","journal-title":"Blood Cancer J"},{"key":"95_CR32","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_390334","volume":"43","author":"HS Ngu","year":"2023","unstructured":"Ngu HS, Savage KJ. Frontline management of nodal peripheral T-cell lymphomas. Am Soc Clin Oncol Educ Book. 2023;43: e390334.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"9","key":"95_CR33","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1182\/blood.2021015114","volume":"140","author":"M Brink","year":"2022","unstructured":"Brink M, Meeuwes FO, van der Poel MWM, Kersten MJ, Wondergem M, Mutsaers PGNJ, et al. Impact of etoposide and ASCT on survival among patients aged <65 years with stage II to IV PTCL: a population-based cohort study. Blood. 2022;140(9):1009\u201319.","journal-title":"Blood"},{"key":"95_CR34","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1093\/annonc\/mdx787","volume":"29","author":"G Fossard","year":"2018","unstructured":"Fossard G, Broussais F, Coelho I, Bailly S, Nicolas-Virelizier E, Toussaint E, et al. Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers. Ann Oncol. 2018;29:715\u201323.","journal-title":"Ann Oncol"},{"key":"95_CR35","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1002\/cncr.31861","volume":"125","author":"SI Park","year":"2019","unstructured":"Park SI, Horwitz SM, Foss FM, Pinter-Brown LC, Carson KR, Rosen ST, et al. The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: report from COMPLETE, a prospective, multicenter cohort study. Cancer. 2019;125:1507\u201317.","journal-title":"Cancer"}],"container-title":["Blood Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44313-025-00095-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s44313-025-00095-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44313-025-00095-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T10:13:55Z","timestamp":1757412835000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s44313-025-00095-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,21]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["95"],"URL":"https:\/\/doi.org\/10.1007\/s44313-025-00095-1","relation":{},"ISSN":["2287-979X","2288-0011"],"issn-type":[{"value":"2287-979X","type":"print"},{"value":"2288-0011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,21]]},"assertion":[{"value":"9 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures involving human participants in this study were conducted in accordance with the ethical standards of the institutional and\/or national research committee, as well as the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"47"}}